Avelumab maintenance fails to extend OS in advanced gastric, gastroesophageal junction cancers

A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer failed to meet its primary endpoints.The multicenter, open-label JAVELIN Gastric 100 study included 805 patients who had not received chemotherapy for metastatic or locally advanced disease. Investigators enrolled patients regardless of PD-L1 expression.All patients underwent induction chemotherapy with oxaliplatin and either 5-FU or capecitabine for 12 weeks.After chemotherapy, 499Read More

Share on facebook
Share on twitter
Share on linkedin